$CDIO

Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics, headquartered in Chicago, develops and commercializes cardiovascular disease tests and related software using its AI-driven Multi-Omics Engine. Its clinical products are Epi+Gen CHD, a blood test assessing three-year risk of a coronary heart disease event, and PrecisionCHD, a blood test for detecting coronary heart disease. PrecisionCHD is paired with Actionable Clinical Intelligence, which provides clinicians with patient-specific insights to support care management. Cardio also offers CardioInnovate360, a research-use-only solution for biopharmaceutical discovery and development, and HeartRisk, a platform providing population-level cardiovascular risk insights to healthcare organizations and other stakeholders. Cardio sells tests and software to healthcare providers and organizations, employers, payors and other channel partners. It also provides research-use-only services to biopharmaceutical companies. Its tests are performed as laboratory-developed tests, and the company is setting up a CLIA high-complexity testing laboratory.

0
1
0

No SEC Form 4 filings for $CDIO in the last 30 days.

See all $CDIO insider activity →
Low

Cardio Diagnostics to host investor call on heart disease test

Cardio Diagnostics (CDIO) will host an investor call on Dec 10, 2026, to discuss its cardiovascular disease detection tech, including data on NOCAD detection and FDA Breakthrough Device designation. The company will also update on its commercial tests, studies, and international expansion to India. CDIO uses epigenetics, genetics, and AI for disease prevention and detection.

Cardio Diagnostics Holdings, Inc. (CDIO): Submission of Matters to a Vote of Security Holders

Cardio Diagnostics Holdings, Inc. (CDIO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 18, 2026, Cardio Diagnostics Holdings, Inc., a Delaware corporation (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). Of the Company’s 2,959,469 shares of common stock issue

CDIO sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning CDIO (Cardio Diagnostics Holdings, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent CDIO coverage spans financial news, earnings and corporate actions.

What's driving CDIO

AlphAI scores every news story that mentions CDIO with an AI model for sentiment and relevance, and aggregates insider trades from Cardio Diagnostics Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CDIO

Score

Cardio Diagnostics to host investor call on heart disease test

Cardio Diagnostics (CDIO) will host an investor call on Dec 10, 2026, to discuss its cardiovascular disease detection tech, including data on NOCAD detection and FDA Breakthrough Device designation. The company will also update on its commercial tests, studies, and international expansion to India. CDIO uses epigenetics, genetics, and AI for disease prevention and detection.

$CDIOLowShareholder vote

Cardio Diagnostics Holdings, Inc. (CDIO): Submission of Matters to a Vote of Security Holders

Cardio Diagnostics Holdings, Inc. (CDIO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 18, 2026, Cardio Diagnostics Holdings, Inc., a Delaware corporation (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). Of the Company’s 2,959,469 shares of common stock issue

Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City

Cardio Diagnostics (CDIO) launched its in-house, CLIA-certified lab in Iowa City, gaining full control over test processing for its Epi+Gen CHD™ and PrecisionCHD™ tests. The move is expected to improve margins to 40% at scale, reduce turnaround times, and enhance research capabilities. The company has secured licenses in several states and aims to expand its cardiovascular health monitoring system.

Cardio Diagnostics Holdings Inc. - Warrant (NQ: CDIOW)

This article provides detailed real-time stock information for Cardio Diagnostics Holdings Inc. - Warrant (CDIOW) listed on Nasdaq. It includes current pricing, trading volume, bid/ask details, historical price ranges, and performance metrics over various periods. The content also features recent news headlines and answers frequently asked questions about the company's publicly traded status and exchange.

Key Market Insights

Cardio Diagnostics Holdings Inc. (CDIO) stocks surged by 16.09%, driven by optimistic market sentiment ahead of a strategic investor call to unveil AI-powered cardiac testing technologies. Despite current negative profitability metrics and fiscal strains, the company maintains strong liquidity. Technical analysis reveals recent volatility, with key resistance and support levels noted, and future prospects largely depend on effectively translating innovation into financial resilience and clear revenue generation.

Related tickers